Đánh giá hiệu quả kỹ thuật nút mạch hóa chất (TACE) trong điều trị ung thư biểu mô tế bào gan tại Bệnh viện Hữu nghị Việt Nam – Cuba Đồng Hới

Hepatocellular carcinoma (HCC) represents a significant global health challenge, standing as a leading cause of cancer-related mortality, and is particularly prevalent in Vietnam, often presenting at intermediate or advanced stages. Transarterial chemoembolization (TACE) has emerged as a critical standard treatment for patients with intermediate-stage HCC or those ineligible for curative surgical options, offering substantial benefits in disease control. While TACE is routinely employed in clinical practice, a comprehensive and systematic evaluation of its effectiveness, safety, and associated prognostic factors within specific regional medical centers, such as Viet Nam – Cuba Dong Hoi Friendship Hospital, remains crucial. This study aims to fill this knowledge gap by rigorously assessing the efficacy and safety of TACE for HCC and identifying key factors influencing patient outcomes, thereby refining clinical protocols.

Oncologists, interventional radiologists, hepatologists, gastroenterologists, and researchers in oncology and diagnostic imaging.

This prospective, descriptive, and analytical study rigorously evaluated the effectiveness and safety of Transarterial Chemoembolization (TACE) for patients with Hepatocellular carcinoma (HCC) at Viet Nam – Cuba Dong Hoi Friendship Hospital. Conducted from March 2020 to December 2024, the study included 50 HCC patients who underwent TACE. Treatment response was meticulously assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST), a well-established standard for evaluating tumor viability post-treatment. Logistic regression analysis was employed to identify significant prognostic factors impacting treatment success. The findings revealed a high overall treatment response rate following TACE, with an encouraging increase in the proportion of complete responses observed over time. Notably, a tumor size of less than 5 cm was identified as a strong independent predictor for early response to treatment, while the presence of solitary tumors was significantly associated with a favorable mid-term response. Crucially, the study reported no major complications or procedure-related mortality, underscoring the safety profile of TACE. These results affirm TACE as an effective and safe treatment modality for HCC in this clinical setting. The identification of key prognostic factors, such as tumor size and tumor multiplicity, offers valuable insights for clinicians, facilitating improved patient selection and personalized treatment strategies, ultimately enhancing patient outcomes and reinforcing TACE's role as a standard of care.